aMoon’s second healthtech fund tops out at $750 million
The Marius Nacht led fund raised an additional $90 million from Credit Suisse and other major institutional investors in Israel and abroad
Hagar Ravet | 12:02 22.07.2020
Israel-based life sciences venture capital firm aMoon’s second fund has reached $750 million in commitments. In March 2019, the fund that was founded by Marius Nacht, the co-founder of firewall pioneer Check Point Software Technologies Ltd., announced it had raised a total of $660 million. The additional $90 million announced now brings aMoon II, which focuses on investments in companies that are in advanced stages, to its maximum allowed cap. aMoon named Credit Suisse among the central investors in the fund, who led the round together with the VC firm as part of their strategic partnership. The round included new commitments from previous investors both Israeli and international, including additional major institutional investors, as well as commitments by new investors from the U.S., Australia, Latin America, and Europe.